These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 27262225)

  • 21. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients.
    Ten Cate H; Lensing AWA; Weitz JI; Middeldorp S; Beyer-Westendorf J; Kubitza D; Brighton T; Raskob GE; Mismetti P; Prandoni P; Gebel M; Prins MH
    Thromb Res; 2018 Oct; 170():75-83. PubMed ID: 30121419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials.
    Beyer-Westendorf J; Lensing AW; Arya R; Bounameaux H; Cohen AT; Wells PS; Middeldorp S; Verhamme P; Hughes R; Kucher N; Pap AF; Trajanovic M; Prins MH; Prandoni P; Weitz JI
    Thromb Res; 2017 Jan; 149():29-37. PubMed ID: 27886530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
    Cohen AT; Dobromirski M
    Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
    Di Nisio M; Vedovati MC; Riera-Mestre A; Prins MH; Mueller K; Cohen AT; Wells PS; Beyer-Westendorf J; Prandoni P; Bounameaux H; Kubitza D; Schneider J; Pisters R; Fedacko J; Fontes-Carvalho R; Lensing AW
    Thromb Haemost; 2016 Sep; 116(4):739-46. PubMed ID: 27535349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of recurrent venous thromboembolism according to baseline risk factor profiles.
    Prins MH; Lensing AWA; Prandoni P; Wells PS; Verhamme P; Beyer-Westendorf J; Bauersachs R; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Decousus H; Kakkar AK; van Bellen B; Pap AF; Homering M; Tamm M; Weitz JI
    Blood Adv; 2018 Apr; 2(7):788-796. PubMed ID: 29632234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
    Young AM; Marshall A; Thirlwall J; Chapman O; Lokare A; Hill C; Hale D; Dunn JA; Lyman GH; Hutchinson C; MacCallum P; Kakkar A; Hobbs FDR; Petrou S; Dale J; Poole CJ; Maraveyas A; Levine M
    J Clin Oncol; 2018 Jul; 36(20):2017-2023. PubMed ID: 29746227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
    Patel AA; Ogden K; Mody SH; Bookhart B
    J Med Econ; 2015 May; 18(5):323-32. PubMed ID: 25557176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study).
    Romualdi E; Donadini MP; Ageno W
    Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):841-4. PubMed ID: 21809964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rivaroxaban and the EINSTEIN clinical trial programme.
    Cohen AT; Bauersachs R
    Blood Coagul Fibrinolysis; 2019 Apr; 30(3):85-95. PubMed ID: 30920394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
    Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Suh E; Spiro TE; Barnathan ES; Raskob GE;
    N Engl J Med; 2018 Sep; 379(12):1118-1127. PubMed ID: 30145946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study.
    Vadhan-Raj S; McNamara MG; Venerito M; Riess H; O'Reilly EM; Overman MJ; Zhou X; Vijapurkar U; Kaul S; Wildgoose P; Khorana AA
    Cancer Med; 2020 Sep; 9(17):6196-6204. PubMed ID: 32663379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [EINSTEIN CHOICE: Comparison of rivaroxaban treatment and prophylactic doses with aspirin in the extended treatment of patients with venous thromboembolism].
    Kaymaz C
    Turk Kardiyol Dern Ars; 2017 Sep; 45(Suppl 4):1-7. PubMed ID: 28947723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies.
    Khorana AA; Weitz JI
    Thromb Haemost; 2018 May; 118(S 01):S23-S33. PubMed ID: 29566417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach.
    Arcelus JI; Domènech P; Fernández-Capitan Mdel C; Guijarro R; Jiménez D; Jiménez S; Lozano FS; Monreal M; Nieto JA; Páramo JA
    Clin Appl Thromb Hemost; 2015 May; 21(4):297-308. PubMed ID: 25504999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.
    Kreutz R; Mantovani LG; Haas S; Monje D; Schneider J; Bugge JP; Gebel M; Tamm M; Ageno W; Turpie AGG
    Thromb Res; 2019 Apr; 176():125-132. PubMed ID: 30825694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Practical management of rivaroxaban for the treatment of venous thromboembolism.
    Imberti D; Benedetti R
    Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis.
    Kohn CG; Lyman GH; Beyer-Westendorf J; Spyropoulos AC; Bunz TJ; Baker WL; Eriksson D; Meinecke AK; Coleman CI
    J Natl Compr Canc Netw; 2018 May; 16(5):491-497. PubMed ID: 29752323
    [No Abstract]   [Full Text] [Related]  

  • 40. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
    Jugrin AV; Hösel V; Ustyugova A; De Francesco M; Lamotte M; Sunderland T
    J Med Econ; 2016; 19(1):1-10. PubMed ID: 26390231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.